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Frequency of a BRAF
V600E mutation in anaplastic thyroid carcinoma, which is thought to be derived mainly from papillary carcinoma by
multi-step carcinogenesis, is much lower than that in papillary carcinomas. To clarify this phenomenon, we analysed BRAF
V600E
mutation in 20 cases of anaplastic carcinoma and 13 accompanying differentiated carcinomas. Among twenty cases of anaplastic
carcinomas, nine and four accompanied papillary and follicular carcinomas, respectively. BRAF
V600E mutation was found in four (20%)
cases. BRAF
V600E mutation was found in three of nine (33.3%), none of four and one of seven (14.3%) anaplastic carcinomas with
papillary carcinoma, follicular carcinoma and without differentiated components, respectively. All three papillary carcinomas
accompanied by anaplastic carcinoma with a BRAF
V600E mutation were also shown to have a BRAF
V600E mutation. In summary,
BRAF
V600E mutation was occasionally observed in anaplastic carcinomas with papillary carcinoma, and the low frequency of BRAF
V600E
mutation in anaplastic carcinoma was thought to be due to the low frequency of anaplastic carcinomas with papillary carcinoma.
These findings raise a question about the classical model of anaplastic transformation and suggest some roles of thyroid cancer stem
cells in the generation of anaplastic carcinoma.
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Thyroid carcinomas are thought to be generated from normal
thyroid follicular cells (thyrocytes) by multi-step carcinogenesis
(Farid et al, 1994). According to this hypothesis, anaplastic
carcinomas are generated from both follicular and papillary
carcinomas by genomic changes, such as mutations in TP53.
Follicular carcinomas are generated from follicular adenomas,
while papillary carcinomas are derived from some unknown
precursor cells that are generated from normal thyrocytes.
Recently, a somatic point mutation in the BRAF gene has been
identified as the most common genetic event in papillary thyroid
carcinoma (Kimura et al, 2003). Most of the tumours with a
mutation harboured a thymine-to-adenine transversion at nucleo-
tide position 1799, which results in a valine-to-glutamic acid
substitution at residue 600 (V600E). Previous reports indicated
that BRAF mutations in thyroid tumours are generally restricted to
papillary carcinoma, and usually there is no mutation in other
types of well-differentiated thyroid cancers, including follicular
carcinoma, Hu ¨rthle carcinoma and medullary carcinoma, as well
as in benign thyroid tumours. The frequency of the mutations in
papillary carcinomas is ranged from 29 to 83% of papillary
carcinoma (Xing, 2005).
It remains controversial whether this gene is also mutated in
anaplastic thyroid carcinomas. In iodine-sufficient areas such as
Japan, papillary carcinoma accounts for 90% of thyroid differ-
entiated carcinomas and follicular carcinoma is rare (Hay, 1990).
When multi-step carcinogenesis is taken into account, a consider-
able number of anaplastic carcinomas with BRAF mutations
should be found. In previous reports, however, the frequency of
the BRAF mutation was only about 10% on average and ranged
from 0 to 63% (Fukushima et al, 2003; Namba et al, 2003;
Nikiforova et al, 2003; Begum et al, 2004; Soares et al, 2004; Xing
et al, 2004; Quiros et al, 2005). Among these studies, some reported
that the BRAF mutation is found frequently only in anaplastic
carcinomas with a papillary carcinoma component, although these
studies have examined only four or five cases. A study examining a
larger number of samples is essential to clarify the role of the BRAF
mutation in anaplastic carcinoma.
Considering these facts, we examined BRAF
V600E mutation in 20
anaplastic carcinomas and 13 accompanying differentiated carci-
nomas and found a low frequency of BRAF
V600E mutation in
anaplastic carcinomas due to the low frequency of anaplastic
carcinomas accompanied by papillary carcinoma.
MATERIALS AND METHODS
Twenty anaplastic carcinomas were used in this study. Among
these cases, nine accompanied papillary carcinoma and four
accompanied follicular carcinoma. Twenty papillary carcinomas
without an undifferentiated component were also examined. These
tumours were surgically resected at Kuma Hospital after obtaining
the patient’s informed consent. The experimental protocol was
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sapproved by the local ethical committee. Paraffin-embedded
tissues were microdissected to separately study well-differentiated
and anaplastic areas within the same tumour nodule. For
microdissection, 8mm sections from a paraffin-embedded tissue
were put on glass slides and weakly stained with haematoxylin and
eosin. The areas of interest (approximately up to 0.5cm
2) were
microdissected using the AS LMD (Leica, Tokyo, Japan). Genomic
DNA was isolated using a QIAamp DNA Mini Kit (Qiagen, Tokyo,
Japan). Ten microlitres of DNA extracted from each tumour
sample was examined by direct sequencing after amplification by
polymerase chain reaction (PCR). To avoid carryover contamina-
tion, Platinum Quantitative PCR SuperMix-UDG (Invitrogen
Japan, Tokyo, Japan) was used for PCR amplification. Fifty
microlitres of PCR mixture contained 0.5mM of each primer, 1ml
of 50mM magnesium chloride, 10ml of extracted DNA and 25mlo f
Platinum Quantitative PCR SuperMix-UDG. The primers used
were
BRF: 50-ACTCTTCATAATGCTTGCTCTGATAG -30 and
BRR: 50-CTGATGGGACCCACTCCA -30
The PCR conditions were 501C for 2min, 951C for 2min and 40
cycles of 951C for 15s and 601C for 1min. The PCR products were
separated on agarose gel and extracted with a QIAquick Gel
Extraction Kit (Qiagen). Purified fragments were sequenced using
a BigDye Terminator Cycle Sequencing FS Ready Reaction Kit with
an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Tokyo,
Japan).
RESULTS
The results of the mutation analysis are summarised in Tables 1
and 2. BRAF
V600E mutation was found in 4 (20%) of 20 anaplastic
carcinomas and in 9 (45%) of 20 papillary carcinomas without an
anaplastic carcinoma examined as controls.
Among the 20 cases of anaplastic carcinomas, 9 and 4 were
accompanied by papillary and follicular carcinomas, respectively.
BRAF
V600E mutation was found in three of nine (33.3%) anaplastic
carcinomas accompanied by papillary carcinoma, none of four
anaplastic carcinomas accompanied by follicular carcinoma and
one of seven (14.3%) anaplastic carcinomas without differentiated
components. All three papillary carcinomas accompanied by
anaplastic carcinoma with a BRAF
V600E mutation were also shown
to have a BRAF
V600E mutation, whereas there was no BRAF
V600E
mutation in follicular carcinomas with anaplastic carcinoma.
In case 9, a BRAF
V600E mutation was found only in papillary
carcinoma but not in coexisting anaplastic carcinoma (Figure 1).
However, whether these two tumours were derived from the same
precursor was not clear, since a thick connective tissue separated
the two.
DISCUSSION
The results of previous studies on the frequency of a BRAF
V599R
mutation in papillary and anaplastic carcinomas in the Japanese
population are summarised in Table 3. The frequency of a
BRAF
V599R mutation in anaplastic carcinomas is about half of that
in papillary carcinomas. It has generally been thought that most
anaplastic carcinomas are derived from papillary carcinomas by
accumulation of genomic damage, but if this hypothesis is true,
then the present observations are difficult to explain. One possible
explanation is that papillary carcinoma with BRAF
V599R mutation
shows a better prognosis without proceeding to anaplastic
transformation. However, this theory conflicts with some previous
studies showing papillary carcinomas with BRAF
V599R mutation
show a poor prognosis (Xing et al, 2005). Another explanation is
that follicular carcinomas are more likely to transform into an
anaplastic carcinoma than papillary carcinoma. In fact, nine cases
of anaplastic carcinoma with a papillary component showed a high
frequency of BRAF
V599R mutation. This might be partly true, since
even though both follicular and anaplastic carcinomas are rare in
iodine-sufficient countries like Japan, many cases of anaplastic
carcinoma accompanying a follicular carcinoma have been
reported (Yokozawa et al, 1996; Asakawa and Kobayashi, 2002).
However, in our study, there were only four cases of anaplastic
carcinomas with a follicular carcinoma, which is not sufficient to
explain the decreased frequency. Seven of twenty anaplastic
carcinomas did not demonstrate any differentiated components
and BRAF
V599R mutation was detected in only one of these cases.
This seems to be the major cause of the decreased frequency of a
BRAF
V599R mutation in anaplastic carcinomas.
The origin of anaplastic carcinoma is quite puzzling. In multi-
step carcinogenesis, malignant transformation is caused by the
Table 1 BRAF
V600E mutation in anaplastic carcinomas and their
accompanying differentiated carcinomas
No. Gender Age Accompanying DC
BRAF
V600E
AC
Mutation
in DC
1 Male 48 Papillary carcinoma + +
2 Female 63 Papillary carcinoma   
3 Female 80 Papillary carcinoma + +
4 Female 59 Papillary carcinoma   
5 Female 88 Papillary carcinoma + +
6 Female 64 Papillary carcinoma   
7 Male 52 Papillary carcinoma   
8 Female 65 Papillary carcinoma   
9 Female 75 Papillary carcinoma   +
10 Female 35 Follicular carcinoma   
11 Female 61 Follicular carcinoma   
12 Female 57 Follicular carcinoma   
13 Female 62 Follicular carcinoma   
14 Female 77 —  
15 Female 63 —  
16 Female 80 —  
17 Female 82 —  
18 Female 77 — +
19 Female 54 —  
20 Female 85 —  
AC¼anaplastic carcinoma; DC¼differentiated carcinoma.
Table 2 Summary of the BRAF
V600E mutation in anaplastic carcinomas and their accompanying differentiated carcinomas
Histology Total number Mutation (+) Mutation ( )
All anaplastic carcinomas 20 4 (20%) 16 (80%)
Anaplastic carcinoma with papillary carcinoma 9 3 (33.3%) 6 (66.7%)
Anaplastic carcinoma with follicular carcinoma 4 0 (0%) 4 (100%)
Anaplastic carcinoma without differentiated carcinoma 7 1 (14.3%) 6 (85.7%)
Papillary carcinoma with anaplastic carcinoma 9 4 (44.4%) 5 (55.6%)
Follicular carcinoma with anaplastic carcinoma 4 0 (0%) 4 (100%)
Papillary carcinoma without anaplastic carcinoma 20 9 (45%) 11 (55%)
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saccumulation of genomic damage in cancer cells. It is thought that
anaplastic carcinoma arises by malignant transformation of
coexisting papillary carcinoma. However, our present findings
indicate that papillary carcinoma with BRAF mutation, which
comprises a considerable percentage of differentiated thyroid
carcinomas, might not be the major origin of anaplastic
carcinoma. Similar phenomena are observed in other genes.
Rearrangement of the RET and PAX8-PPARg1 gene is found
frequently in papillary and follicular carcinomas, respectively, but
not in anaplastic carcinomas (Tallini et al, 1998; Kroll et al, 2000).
Considering these discrepancies, a new hypothesis of thyroid
carcinogenesis, fetal cell carcinogenesis, in which cancer cells are
derived from the remnants of fetal thyroid cells, instead of normal
thyroid follicular cells, has been presented (Takano, 2004, 2007;
Takano and Amino, 2005). In this hypothesis, the origins of
anaplastic carcinoma are not differentiated carcinoma cells but
certain kinds of fetal thyroid cells, possibly cells with a close
relationship with thyroid stem cells. It is noted that in this
hypothesis, the role of BRAF mutation is the prevention of
immature fetal thyroid cells, namely thyroblasts that are the
origins of papillary carcinomas, from differentiating into follicle-
forming cells, such as follicular tumour cells or thyrocytes.
In multi-step carcinogenesis (Figure 2), the present data are
explained as follows. A thyrocyte is transformed into a papillary
carcinoma cell by a BRAF mutation and it is further transformed
into an anaplastic carcinoma cell by a TP53 mutation. A thyrocyte
without BRAF mutation is transformed into a follicular carcinoma
cells and is further transformed into an anaplastic carcinoma cell
by a TP53 mutation. A considerable number of anaplastic
carcinomas are derived from some unknown precursors, which
remain silent for many years without proliferation.
In fetal cell carcinogenesis, the present data are explained as
follows. Both anaplastic carcinoma cells and differentiated
carcinomas cells are derived from the same origin, probably
thyroid cancer stem cells. In other words, thyroid cancer stem cells
can produce either anaplastic carcinoma cells or differentiated
cancer cells. Since a BRAF mutation blocks a papillary carcinoma
cell from differentiating into follicular cells, a thyroid cancer stem
cell with BRAF mutation produces anaplastic carcinoma cells and
papillary carcinoma cells, but not follicular carcinoma cells. On the
contrary, thyroid cancer stem cells without BRAF mutation
produce anaplastic carcinoma cells and follicular carcinoma cells,
since the papillary carcinoma cells that were produced further
differentiate immediately into follicular cells. Occasionally, thyroid
cancer stem cells maintain an undifferentiated property and
proliferate without producing differentiated carcinoma cells,
resulting in the formation of anaplastic carcinoma without
differentiated components. Late onset of anaplastic carcinoma is
easily understood when the origin of anaplastic carcinoma is a
thyroid stem cell, since a stem cell can stay silent without
proliferation for many years (Reya et al, 2001). Similarly, the
Papillary carcinoma Anaplastic carcinoma
Figure 1 Haematoxylin and eosin-stained section and the results of sequencing analysis in case 9. Upper and lower panels show high ( 200) and low
magnification of a section, respectively. Areas indicated by white arrows were microdissected and the sequence of the BRAF gene was analysed. A
heterozygous missense mutation (T1799A/V600E) was identified in exon 15 in a papillary carcinoma sample (left) but not in a coexisting anaplastic
carcinoma sample (left).
Table 3 BRAF
V600E mutation in papillary and anaplastic carcinomas in the
Japanese population
Papillary carcinoma Anaplastic carcinoma
Reference Positive/total cases % Positive/total cases %
Fukushima et al (2003) 40/76 52.6 0/7 0
Namba et al (2003) 49/170 28.8 2/6 33.3
This study 9/20 45.0 4/20 20.0
Total 98/266 36.8 6/33 18.2
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spossibility that thyroid cancer stem cells are the unknown origin of
anaplastic carcinoma might also be taken into consideration in
multi-step carcinogenesis.
It will be a direct proof of fetal cell carcinogenesis hypothesis
when a BRAF mutation is observed only in coexisting papillary
carcinoma but not in anaplastic carcinoma. Case 9 is such a case.
However, the relation of these two tumours is not clear, since they
were separated by a connective tissue. At least in this case,
anaplastic carcinoma is not derived from coexisting papillary
carcinoma but from an unknown origin. Analysing more cases in
the same way may lead to the finding of similar cases with
discrepant genetic alternation, since a relatively small number of
cases were engaged in our and previous studies, due to the rarity of
anaplastic carcinoma.
Although the mechanism of anaplastic transformation has not
been understood, the recent advances in cancer research, the
elucidation of cancer stem cells, may provide new perspectives that
will contribute to clarifying the nature of anaplastic carcinoma.
The present study may facilitate an understanding of the relation
between anaplastic carcinoma and coexisting differentiated
carcinomas.
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Figure 2 Anaplastic transformation in multi-step carcinogenesis and fetal cell carcinogenesis. In multi-step carcinogenesis (A), anaplastic carcinoma cells
are generated by three pathways. A thyrocyte is transformed into a papillary carcinoma cell by a BRAF mutation, then further transformed into an anaplastic
carcinoma cell. A thyrocyte without a BRAF mutation is transformed into a follicular carcinoma cells, then further transformed into an anaplastic carcinoma
cell. Anaplastic carcinomas are also generated from some unknown precursors. In fetal cell carcinogenesis (B), both anaplastic and differentiated carcinoma
cells are generated from thyroid cancer stem cells. A thyroid cancer stem cell with a BRAF mutation can generate anaplastic or papillary carcinoma cells but
not follicular carcinoma cells, since a BRAF mutation blocks the papillary carcinoma cell from differentiating into a follicular carcinoma cell.
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